Eli Lilly’s diabetes drug Mounjaro is expected to be approved to treat obesity in the near future. It could drive sales for more than a decade.
Drugs that could help tackle the obesity epidemic in the U.S. are causing both medical and market excitement. Eli Lilly can benefit in both the short-term and more than a decade into the future, according to Citi.
“In the near-term, we rely on increasing Mounjaro capacity and forthcoming obesity approval to continue to drive share price momentum,” Baum wrote. Lilly’s Mounjaro is competing with Novo Nordisk’s Ozempic in the class of weight-loss drugs known as incretins which have been shown to suppress appetite and reduce food intake. Lilly is lining up two more drug candidates of the same class, retatrutide and orforglipron.
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Analysis: Anti-obesity drugs can be boost for food makers, investors sayThe growth in demand for appetite suppressing anti-obesity drugs like Novo Nordisk's (NOVOb.CO) Wegovy presents opportunities for food manufacturers and the market's initially downbeat reaction may be overdone, investors say.
Read more »
The Hollywood actors strike hits 100 days. Why hasn't a deal been reached and what's next?The historic Lilly house is open for guests who want a spooky experience.
Read more »
JSO: Woman shot twice while waiting for Uber in Lake Forest areaJSO is investigating after a woman was shot twice on Palmdale Street.
Read more »
Depression in Parents May Influence Children's WeightThe skyrocketing rates of obesity and mental illness are related. Integrating treatment and prevention strategies offers hope for better solutions.
Read more »